ProQR Therapeutics (PRQR) to Release Quarterly Earnings on Thursday

Key Points

• ProQR Therapeutics will report Q1 2026 results before the market opens on Thursday, May 14, 2026, with analysts projecting EPS of ($0.15) and $5.189 million in revenue; the earnings call is set for 12:30 PM ET.
• The company recently missed estimates—posting EPS of ($0.09) vs. ($0.08) expected—has negative return on equity and net margin, and analysts forecast roughly ‑$1 EPS for both the current and next fiscal year.
• Shares trade near $1.72 with a market capitalization of about $181.2M, and the consensus analyst view is a Moderate Buy with a $7.25 average price target, though ratings are mixed (six Buys, one Hold, one Sell).

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) is projected to release its Q1 2026 results before the market opens on Thursday, May 14th. Analysts expect ProQR Therapeutics to post earnings of ($0.15) per share and revenue of $5.1890 million for the quarter. Parties may visit the the company's upcoming Q1 2026 earning results page for the latest details on the call scheduled for Thursday, May 14, 2026 at 12:30 PM ET.

ProQR Therapeutics (NASDAQ:PRQR - Get Free Report) last posted its quarterly earnings results on Thursday, March 12th. The biopharmaceutical company reported ($0.09) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.08) by ($0.01). ProQR Therapeutics had a negative return on equity of 65.89% and a negative net margin of 255.83%.The company had revenue of $5.53 million during the quarter, compared to analysts' expectations of $6.12 million. On average, analysts expect ProQR Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

ProQR Therapeutics Stock Performance

Shares of PRQR opened at $1.72 on Thursday. The company has a market capitalization of $181.22 million, a PE ratio of -3.74 and a beta of 0.08. The company's 50 day moving average price is $1.69 and its 200 day moving average price is $1.92. ProQR Therapeutics has a 52 week low of $1.33 and a 52 week high of $3.10.

Hedge Funds Weigh In On ProQR Therapeutics

Several hedge funds and other institutional investors have recently added to or reduced their stakes in PRQR. Osaic Holdings Inc. lifted its stake in shares of ProQR Therapeutics by 59.6% in the second quarter. Osaic Holdings Inc. now owns 12,050 shares of the biopharmaceutical company's stock worth $25,000 after buying an additional 4,500 shares during the last quarter. Guggenheim Capital LLC acquired a new position in ProQR Therapeutics in the 4th quarter valued at $35,000. Invesco Ltd. acquired a new position in ProQR Therapeutics in the 4th quarter valued at $51,000. Simplex Trading LLC raised its holdings in ProQR Therapeutics by 44,169.0% in the 4th quarter. Simplex Trading LLC now owns 44,269 shares of the biopharmaceutical company's stock worth $89,000 after acquiring an additional 44,169 shares during the period. Finally, Persistent Asset Partners Ltd raised its holdings in ProQR Therapeutics by 24.5% in the 4th quarter. Persistent Asset Partners Ltd now owns 45,154 shares of the biopharmaceutical company's stock worth $91,000 after acquiring an additional 8,874 shares during the period. Institutional investors and hedge funds own 32.65% of the company's stock.

Analyst Upgrades and Downgrades

A number of equities research analysts have issued reports on PRQR shares. Chardan Capital reissued a "buy" rating and set a $4.00 target price on shares of ProQR Therapeutics in a research note on Thursday, April 9th. Citigroup reiterated a "market outperform" rating on shares of ProQR Therapeutics in a report on Friday, March 13th. Wall Street Zen raised ProQR Therapeutics from a "strong sell" rating to a "hold" rating in a research report on Saturday, March 14th. Oppenheimer began coverage on ProQR Therapeutics in a research note on Thursday, March 12th. They issued an "outperform" rating and a $9.00 target price on the stock. Finally, Weiss Ratings reaffirmed a "sell (d-)" rating on shares of ProQR Therapeutics in a research report on Tuesday, April 21st. Six investment analysts have rated the stock with a Buy rating, one has given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, ProQR Therapeutics presently has an average rating of "Moderate Buy" and a consensus price target of $7.25.

About ProQR Therapeutics

ProQR Therapeutics N.V. is a clinical-stage biotechnology company dedicated to developing RNA-based therapies for severe genetic diseases. Utilizing its proprietary Axiomer® RNA editing platform, ProQR aims to correct disease-causing mutations directly at the messenger RNA level. The company's pipeline features several investigational candidates, including sepofarsen (formerly QR-110) for Leber congenital amaurosis type 10, QR-421a targeting Usher syndrome and certain forms of retinitis pigmentosa, and QR-313 for dystrophic epidermolysis bullosa.

Founded in 2012 and headquartered in Leiden, the Netherlands, ProQR maintains a significant presence in Cambridge, Massachusetts, to support its clinical research and regulatory initiatives.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.